Work

INTERCEPT-AD Biomarker Results: Early Effect of Sabirnetug Treatment on Synaptic Biomarkers in Alzheimer’s Disease (P12-3.003)

Year: 2025

Type: article

Abstract: To examine early effects of sabirnetug (ACU193) on cerebrospinal fluid (CSF) levels of synaptic biomarkers in study participants with early symptomatic Alzheimer’s disease (AD).

Source: Neurology

DOI: 10.1212/wnl.0000000000211373

Authors: Elizabeth Johnson, Erika N. Cline, Karen Sundell, Daniel Antwi-Berko, Marleen JA Koel-Simmelink, Charlotte Teunissen, Eric Siemers, Hao Zhang, Maddelyn Hyland, Gopalan Sethuraman, Hugo Vanderstichele, June Kaplow, Robert A. Dean, Jasna Jerecic

Institutions: Acumen Pharmaceuticals (United States), Amsterdam University Medical Centers

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4409225670

FWCI:

Cites:

Cited by:

Related to: 10